AME Logo
ML

Mireille Laforge

PhD

Inserm U1141 – NeuroDiderot at Université Paris Cité, France

Biography

Mireille Laforge is a CNRS researcher and leads the 3I Brain team within Inserm U1141 – NeuroDiderot at Université Paris Cité. She is also involved in scientific activities at the Robert-Debré Institute for Child Brain Research, at the interface of immunology, metabolism, and neuroscience.

Her research focuses on the interplay between immune responses, cellular energy metabolism and brain function, with particular emphasis on mechanisms underlying brain development, infectious diseases, neurodevelopmental disorders and autism.

A major area of her research is immunometabolism, investigating how cellular energy metabolism regulates immune-cell function and how metabolic reprogramming can contribute to pathological immune responses and chronic inflammation. Her work also explores the interactions between the immune system and the developing brain, with a particular interest in mechanisms underlying early-life vulnerability and long-term neurological consequences

A specific focus of her current research is immunometabolic dysfunction in AIDS and Long COVID contributing to the identification and characterization of biological signatures associated with disease mechanisms and to the exploration of potential therapeutic avenues.

Her activities also extend to research innovation and translational medicine, with projects aimed at translating discoveries in immunometabolism and disease biology into clinically relevant applications. In 2026, she is one of the investigators leading a project on the immunometabolic profiling of anhedonia, conducted in collaboration with the University of Oxford within the framework of the Precision Mind Prize.

She is also the founder of Astremiha Therapeutics, a biotechnology start-up developing innovative broad-spectrum antiviral strategies, with the overarching goal of translating advances in immunometabolism into biomarkers, diagnostic tools, and novel therapeutic approaches.